Date of Presentation
5-4-2023 12:00 AM
College
School of Osteopathic Medicine
Poster Abstract
Context: The COVID-19 pandemic provided a unique opportunity for urgent expansion of telemedicine services as providers continued to supply longitudinal care to patients. Patients with type II diabetes were vulnerable to serious infection with COVID-19 as well as disruption in management of their chronic disease.
Objective: To delineate the outcomes in type II diabetes patients through the COVID-19 pandemic by a retrospective chart review in which disease management was evaluated through HbA1c levels and BMI.
Methods: This retrospective chart review included adult T2DM patients receiving care from five university family medicine offices in NJ. HbA1c levels and BMI values were compared during the pre-pandemic (February 2019-February 2020) and pandemic (March 2020-May 2022) time periods. Data analysis was completed through SPSS.
Results: There was no significant difference in HbA1c levels from before the COVID-19 pandemic compared to during the pandemic, but there was a significant decrease in BMI. There was a greater shift in patients being prescribed multiple anti-diabetic oral drugs compared to insulin during the COVID-19 pandemic.
Conclusions: Despite changes in daily living and healthcare delivery, patients with T2DM were able to maintain or improve their disease status. Patients that were older, female, with a higher BMI, and of African American descent exhibited greater healthcare utilization, with variance in types of visits and associated outcomes. Moving forward, telemedicine could be a potential outlet for alleviating the global health burden associated with T2DM.
Keywords
Diabetes Mellitus, COVID-19, Pandemics, Health Care, Outcome Assessment, Telemedicine, Glycemic Control
Disciplines
Endocrine System Diseases | Endocrinology, Diabetes, and Metabolism | Family Medicine | Health Services Administration | Medicine and Health Sciences | Nutritional and Metabolic Diseases | Telemedicine | Therapeutics
Document Type
Poster
Included in
Endocrine System Diseases Commons, Endocrinology, Diabetes, and Metabolism Commons, Family Medicine Commons, Health Services Administration Commons, Nutritional and Metabolic Diseases Commons, Telemedicine Commons, Therapeutics Commons
Outcomes in Type II Diabetes Patients through the Covid 19 Pandemic A Retrospective Chart Review
Context: The COVID-19 pandemic provided a unique opportunity for urgent expansion of telemedicine services as providers continued to supply longitudinal care to patients. Patients with type II diabetes were vulnerable to serious infection with COVID-19 as well as disruption in management of their chronic disease.
Objective: To delineate the outcomes in type II diabetes patients through the COVID-19 pandemic by a retrospective chart review in which disease management was evaluated through HbA1c levels and BMI.
Methods: This retrospective chart review included adult T2DM patients receiving care from five university family medicine offices in NJ. HbA1c levels and BMI values were compared during the pre-pandemic (February 2019-February 2020) and pandemic (March 2020-May 2022) time periods. Data analysis was completed through SPSS.
Results: There was no significant difference in HbA1c levels from before the COVID-19 pandemic compared to during the pandemic, but there was a significant decrease in BMI. There was a greater shift in patients being prescribed multiple anti-diabetic oral drugs compared to insulin during the COVID-19 pandemic.
Conclusions: Despite changes in daily living and healthcare delivery, patients with T2DM were able to maintain or improve their disease status. Patients that were older, female, with a higher BMI, and of African American descent exhibited greater healthcare utilization, with variance in types of visits and associated outcomes. Moving forward, telemedicine could be a potential outlet for alleviating the global health burden associated with T2DM.